ACM
INSY

Atika Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Atika Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-102,000
Closed -$1.98M – 82
2014
Q3 		$1.98M Buy
+102,000
New +$1.6M 1.52% 28
2014
Q2 		– Sell
-99,624
Closed -$2.06M – 83
2014
Q1 		$2.06M Buy
+99,624
New +$1.98M 1.76% 22

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

Atika Capital Management's INSY Position: Q4 2014 in Review

Atika Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2014, closing a stake of 102,000 shares — an estimated $1.98M sold.

Atika Capital Management first reported a position in INSY in Q1 2014 and held it in 2 quarters. The position peaked at $2.06M in Q1 2014. 113 funds tracked by Wall St. Rank hold INSY as of Q4 2014.

  • Atika Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2014 after selling out during the quarter.
  • Atika Capital Management sold 102,000 Insys Therapeutics, Inc. shares in Q4 2014, an estimated $1.98M.
  • Atika Capital Management first reported a position in Insys Therapeutics, Inc. in Q1 2014 and held it in 2 quarters.
  • Atika Capital Management's Insys Therapeutics, Inc. position peaked at $2.06M in Q1 2014.
  • 113 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2014.

Based on Atika Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.